GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - PROKIDNEY CORP

Explicit Guidance:

• Enrollment Completion: Anticipate finishing patient enrollment for the Phase 3 ROPARINCEL (roparazole) trial in Q1 2027.
• Clinical Readouts: Expect an accelerated regulatory approval readout based on eGFR slope in Q2 2027; a confirmatory endpoint (time to composite events including dialysis/transplant) will follow assuming accelerated approval.
• Financial Runway: Company held $142 million in cash as of September 2024, sufficient to fund operations through mid-2027 post-data readout.

Business-Segment Outlook:

• Launch Strategy: Initial commercial launch planned for a focused, purposeful rollout at 8–10 centers of excellence (renal partnership networks) to ensure patient identification and procedural pathways are established.
• Manufacturing Capacity:
  • Year 1 (Launch): Capacity for 350 patients at the Winston-Salem, NC facility.
  • Year 2: Capacity expansion via tech transfer to add 500 patients (total 850).
  • Year 3: Further expansion to add another 500 patients (total 1,350).
  • Year 3–4: Goal to reach total annual capacity of approximately 3,000 patients through facility expansion, CDMO usage, or geographical replication.
• Commercial Scaling: Will scale capacity by validating the initial 8–10 center model and replicating it as manufacturing capacity increases.

Market and Competitive Outlook:

• Target Population (TAM): Identifies a Total Addressable Market of over 1.1 million U.S. patients with Stage 3B/4 CKD and Type 2 Diabetes.
• Pricing Strategy: Anticipates pricing in the range of cell therapy or rare disease products (approaching established high-price tiers), pending data compellency and payer resonance.
• Complementary Use: Product intended for patients progressing despite optimal standard of care, specifically those on SGLT2 inhibitors, RAS inhibitors (ACE/ARB), and potentially GLP-1s.
• Competitive Moat: Relies on high clinical trial execution complexity, proprietary know-how (biopsy/injection protocol, manufacturing process), and a first-mover advantage in autologous cell therapy for CKD.

Macro / Industry Outlook:

• Policy Environment: Positioned favorably under the 2019 Executive Order advancing American kidney health and the recent HHS kidney care plan, which includes a pillar on innovation to stabilize kidney function; expects bipartisan support in the U.S.
• Market Need: Strong clinical consensus that nephrologists have limited options for patients progressing despite "optimized" standard of care; unmet need is a "when, not if" progression to dialysis.
• Geographic Focus: Sole strategic focus remains on the U.S. market due to the size of the unmet need; open to international strategic partnerships post-U.S. launch but not immediate priority.

Strategic Initiatives:

• Phase 3 Trial Design: Randomized, sham-controlled, two-arm, blinded study (GFR 20–35, T2D, CKD) with accelerated approval endpoint (eGFR slope difference).
• Statistical Assumptions: Assuming a control group decline of 3 mL/min/year (conservative vs. observed 6 mL/min/year in Phase 2) and a treated group decline of 1.5 mL/min/year, targeting a 50% treatment effect.
• Technology: Utilizing autologous cell therapy expanded ex vivo without viral vectors or genetic modification, enabling outpatient delivery and avoiding immunosuppression.
• IP Expansion: Strengthening intellectual property position through newly disclosed patent positioning and operational know-how protection.

Risks and Headwinds to Outlook:

• Clinical Outcome: The $142 million cash runway extends only to mid-2027; failure to achieve the Q2 2027 readout with compelling data could jeopardize commercial viability.
• Payer Reimbursement: Success depends on demonstrating clinical value that resonates with payers; pricing acceptance remains an open variable until data is released.
• Commercial Execution: Initial challenge in identifying and funneling patients into the 8–10 specialized centers; reliance on physician referral pathways for the 1.1 million potential patients.
• Operational Scaling: Manufacturing ramp-up requires successful tech transfer and potential facility replication to meet the 3,000-patient/year target.

Management Tone on the Future:

• Confidence Level: High confidence in the mechanism of action (cytoprotective, metabolic stabilization) based on Phase 2 data and preclinical models.
• Strategic Clarity: Management expresses strong conviction in the conservative statistical assumptions for the Phase 3 control arm, believing a 1.5 mL/min difference is both statistically achievable and clinically meaningful.
• Differentiation: Emphasizes the unique nature of the therapy (no viral vectors, outpatient, no immunosuppression) compared to other cell therapies, projecting a smoother commercial path.
• Focus: Unwavering commitment to the U.S. market first to avoid distraction, with international expansion strictly contingent on U.S. success.

Miscellaneous:

• Data Specifics: Phase 2 (RMCL002) showed a 78% improvement in kidney function decline slope (4.5 mL/min annualized difference) in the high-risk GFR <30 cohort.
• Timeline: Recruitment for the Phase 3 trial has stopped; enrollment is ongoing with final patients expected in Q1 2027.
• Regulatory Path: Utilizes RMAT (Regenerative Medicine Advanced Therapy) designation, requiring demonstration of benefit above standard of care.